NAYA buys gene therapy company Florida Biotech for $20m

2024-01-24

临床1期基因疗法并购优先审批

NAYA buys gene therapy company Florida Biotech for $20m

Preview

来源: Pharmaceutical Technology

NAYA will acquire all outstanding shares of Florida Biotech for $20m in shares of the NAYA post-INVO merger. Image Credit: Jozef Micic / Shutterstock.

Preview

来源: Pharmaceutical Technology

Florida-based NAYA Biosciences has entered into a binding letter of intent to acquire Florida Biotechnologies.

The news comes following NAYA’s plans to create an oncology division as part of its merger with Florida-based INVO Biosciences. The merger is expected to close in Q1 2024, as per a 10 November 2023 press release.

NAYA will acquire all outstanding shares of Florida Biotech for $20m in shares of the NAYA post-INVO merger. Florida Biotech will also be eligible to receive $5m in milestone-based payments, as per a 24 January press release. The deal is contingent on the INVO and NAYA merger closing and the merged company having “sufficient financing to further develop the gene therapy programs from Florida Biotech”.

Florida Biotech’s pipeline consists of adeno-associated virus (AAV) vector gene therapies against mitochondrial genetic diseases. The company’s lead candidate is AAV gene therapy for Leber hereditary optic neuropathy (LHON), a rare mitochondrial disorder that causes progressive visual loss due to optic neuropathy in young males.

The LHON gene therapy was developed in collaboration with the University of Miami. The first generation of the therapy has been evaluated in a Phase I trial, with the second-generation product with demonstrating “curative results without any serious adverse events” in preclinical studies for LHON.

The LOHN gene therapy programme received over $6m in grants and qualifies for Regenerative Medicine Advanced Therapy (RMAT) designation and multiple US Food and Drug Administration (FDA) priority review vouchers, as per the company.

NAYA Oncology also brought two clinical-stage bispecific antibody assets for the treatment of hepatocellular carcinoma and multiple myeloma (MM) from Cytovia Therapeutics in preparation for the INVO merger in October 2023. The company published preclinical data for the NY-338/CYT-338, a CD38-targeted Flex-NK bispecific antibody, for the treatment of MM was published as an abstract in the 2023 American Society of Hematology’s (ASH) meeting supplement of Blood in December 2023.

NAYA plans to start clinical trials for both bispecific antibody therapies in 2024. The first-in-human Phase I study for NY-338 in patients with relapsed/refractory MM is currently in preparation.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free WhitepaperCell and gene therapies: Pipe dream to pipeline

The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.

By Cytiva Thematic

Preview

来源: Pharmaceutical Technology

-->

By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构